Home › Hereditary Neoplastic Syndromes › NCT07195071
Feasibility Trial of Combination of Obstetrical Carrier Screening and Hereditary Cancer Screening
Who can join
Ages 18 to 55 · Women · Healthy volunteers welcome
Full eligibility criteria
Inclusion criteria: * Age: 18 years - 55 years * Patients receiving obstetrical-related care at a CUMC-affiliated enrollment site * Patients who have elected to undergo OCS with the CUMC-affiliated obstetrics provider * Patients with prior OCS but planned to repeat OCS are eligible * Patients can speak and read in English or Spanish Exclusion criteria: * Patients who have previously completed a multigene hereditary cancer syndrome panel * Patients that have a hematologic cancer or hematologic pre-cancer * Patients who have a history of an autologous bone marrow transplant
About the study
The investigators hypothesize that preconception and pregnancy may be a feasible and effective time to offer inherited cancer risk screening. This study will assess interest in cancer genetic testing among patients receiving routine prenatal care or preconception care. The goal is to evaluate the acceptability of hereditary cancer testing when offered alongside standard prenatal genetic screening. The study will also explore whether universal screening in this population could support early cancer prevention
What is being tested
- Natera empower comprehensive hereditary cancer panel (device)
- Obstetrical carrier screening (device)
Sponsor: Columbia University · Participants: 1,000 · Started: Feb 12, 2026
Contact the study team
- Jessica Giordano · Phone: 212-305-7250
- Reena Vattakalam · Phone: 212-342-6895
Official record on ClinicalTrials.gov — NCT07195071
Locations in the U.S.
| New York | Columbia University Irving Medical Center, New York |
Conditions
From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.